TY - JOUR
T1 - Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility
AU - Ohashi, Masao
AU - Oyama, Takuji
AU - Putranto, Endy Widya
AU - Waku, Tsuyoshi
AU - Nobusada, Hiromi
AU - Kataoka, Ken
AU - Matsuno, Kenji
AU - Yashiro, Masakazu
AU - Morikawa, Kosuke
AU - Huh, Nam Ho
AU - Miyachi, Hiroyuki
N1 - Funding Information:
This work was supported in part by the Targeted Proteins Research Program of the Japan Science and Technology Corporation (JST), the Uehara Memorial Foundation, the Tokyo Biochemical Research Foundation (TBRF), and the Okayama Foundation for Science and Technology (OFST). The authors would like to thank Nippon Chemiphar Co. Ltd. for transient transfection assays.
PY - 2013/4/15
Y1 - 2013/4/15
N2 - In the continuing study directed toward the development of peroxisome proliferator-activated receptor gamma (hPPARγ) agonist, we attempted to improve the water solubility of our previously developed hPPARγ-selective agonist 3, which is insufficiently soluble for practical use, by employing two strategies: introducing substituents to reduce its molecular planarity and decreasing its hydrophobicity via replacement of the adamantyl group with a heteroaromatic ring. The first approach proved ineffective, but the second was productive. Here, we report the design and synthesis of a series of α-benzyl phenylpropanoic acid-type hPPARγ partial agonists with improved aqueous solubility. Among them, we selected (R)-7j, which activates hPPARγ to the extent of about 65% of the maximum observed with a full agonist, for further evaluation. The ligand-binding mode and the reason for the partial-agonistic activity are discussed based on X-ray-determined structure of the complex of hPPARγ ligand-binding domain (LBD) and (R)-7j with previously reported ligand-LDB structures. Preliminal apoptotic effect of (R)-7j against human scirrhous gastric cancer cell line OCUM-2MD3 is also described.
AB - In the continuing study directed toward the development of peroxisome proliferator-activated receptor gamma (hPPARγ) agonist, we attempted to improve the water solubility of our previously developed hPPARγ-selective agonist 3, which is insufficiently soluble for practical use, by employing two strategies: introducing substituents to reduce its molecular planarity and decreasing its hydrophobicity via replacement of the adamantyl group with a heteroaromatic ring. The first approach proved ineffective, but the second was productive. Here, we report the design and synthesis of a series of α-benzyl phenylpropanoic acid-type hPPARγ partial agonists with improved aqueous solubility. Among them, we selected (R)-7j, which activates hPPARγ to the extent of about 65% of the maximum observed with a full agonist, for further evaluation. The ligand-binding mode and the reason for the partial-agonistic activity are discussed based on X-ray-determined structure of the complex of hPPARγ ligand-binding domain (LBD) and (R)-7j with previously reported ligand-LDB structures. Preliminal apoptotic effect of (R)-7j against human scirrhous gastric cancer cell line OCUM-2MD3 is also described.
KW - Human peroxisome proliferator-activated receptor
KW - PPAR gamma
KW - Partial agonist
KW - Structural biology
UR - http://www.scopus.com/inward/record.url?scp=84875748641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875748641&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2013.02.003
DO - 10.1016/j.bmc.2013.02.003
M3 - Article
C2 - 23490155
AN - SCOPUS:84875748641
SN - 0968-0896
VL - 21
SP - 2319
EP - 2332
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 8
ER -